Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pyxis Oncology Inc PYXS

Healthcare Biotechnology
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma... see more

Recent & Breaking News (NDAQ:PYXS)

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 29, 2023

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer

GlobeNewswire November 28, 2023

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

GlobeNewswire November 7, 2023

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

GlobeNewswire September 27, 2023

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

PR Newswire September 21, 2023

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

GlobeNewswire August 31, 2023

Pyxis Oncology Successfully Completes Acquisition of Apexigen

GlobeNewswire August 23, 2023

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

GlobeNewswire August 11, 2023

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

GlobeNewswire August 1, 2023

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 30, 2023

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

PR Newswire June 15, 2023

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

GlobeNewswire May 30, 2023

Pyxis Oncology to Acquire Apexigen

GlobeNewswire May 24, 2023

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

GlobeNewswire May 11, 2023

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 31, 2023

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

GlobeNewswire March 22, 2023

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

GlobeNewswire March 16, 2023

Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference

GlobeNewswire February 13, 2023

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 23, 2022

Pyxis Oncology Announces FDA Clearance of Two IND Applications

GlobeNewswire December 1, 2022